LON:MXCT MaxCyte Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. GBX 387.50 +7.50 (+1.97%) (As of 07/1/2022 05:06 PM ET) Add Compare Share Today's Range 370▼ 39050-Day Range 292▼ 45052-Week Range 280▼ 1,235Volume11,462 shsAverage Volume70,884 shsMarket Capitalization£393.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address MXCT Stock Forecast (MarketRank)Overall MarketRank™0.91 out of 5 starsAnalyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for MaxCyte. Previous Next 4.5 Community Rank Outperform VotesMaxCyte has received 152 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMaxCyte has received 69 “underperform” votes. (Add your “underperform” vote.)Community SentimentMaxCyte has received 68.78% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about MaxCyte and other stocks. Vote “Outperform” if you believe MXCT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MXCT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMaxCyte does not currently pay a dividend.Dividend GrowthMaxCyte does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MaxCyte insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of MaxCyte is -28.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MaxCyte is -28.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaxCyte has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MaxCyte (LON:MXCT)MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Read More MXCT Stock News HeadlinesMay 13, 2022 | finance.yahoo.comMaxCyte (LON:MXCT) pulls back 22% this week, but still delivers shareholders solid 28% CAGR over 3 yearsMay 9, 2022 | seekingalpha.comMaxCyte, Inc. (MXCT) CEO Doug Doerfler on Q1 2022 Results - Earnings Call TranscriptMay 9, 2022 | finanznachrichten.deMaxCyte, Inc.: MaxCyte Reports First Quarter Financial ResultsMay 9, 2022 | finance.yahoo.comMaxCyte Reports First Quarter Financial ResultsApril 20, 2022 | finance.yahoo.comMaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022April 13, 2022 | marketwatch.comMaxCyte CFO Resigns, Ron Holtz Appointed in Interim; Sees 1Q Revenue UpApril 13, 2022 | proactiveinvestors.comMaxCyte sales surge, CFO stands downApril 12, 2022 | seekingalpha.comMaxCyte reports CFO resignation and Q1 revenue estimateMarch 23, 2022 | benzinga.comMaxCyte's Return On Capital Employed InsightsMarch 22, 2022 | finance.yahoo.comMaxCyte Reports Fourth Quarter and Full Year Financial ResultsMarch 15, 2022 | finance.yahoo.comIs MaxCyte, Inc. (LON:MXCT) Popular Amongst Institutions?March 9, 2022 | finance.yahoo.comMaxCyte, Inc. Names Cenk Sumen Chief Scientific OfficerFebruary 24, 2022 | finance.yahoo.comMaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022See More Headlines Industry, Sector and Symbol Stock ExchangeLON Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolLON:MXCT CUSIPN/A CIKN/A Webwww.maxcyte.com Phone+1-301-9441700FaxN/AEmployees84Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio5.05 Current Ratio17.10 Quick Ratio16.53 Sales & Book Value Annual Sales£38.99 million Price / Sales10.09 Cash FlowGBX 240.95 per share Price / Cash Flow1.61 Book ValueGBX 258.30 per share Price / Book1.50Miscellaneous Outstanding Shares101,540,000Free FloatN/AMarket Cap£393.47 million OptionableNot Optionable BetaN/A MaxCyte Frequently Asked Questions How has MaxCyte's stock performed in 2022? MaxCyte's stock was trading at GBX 755 at the start of the year. Since then, MXCT shares have decreased by 48.7% and is now trading at GBX 387.50. View the best growth stocks for 2022 here. Who are MaxCyte's key executives? MaxCyte's management team includes the following people: Mr. Douglas Arthur Doerfler, Founder, Pres, CEO & Exec. Director (Age 66, Pay $1.39M)Mr. Ronald Evan Holtz CPA, Ph.D., Chief Financial Officer (Age 64, Pay $649.38k)Dr. J. Stark Thompson Ph.D., Consultant (Age 80, Pay $84.71k)Dr. Cenk Sumen, Chief Scientific Officer (Age 49)Mr. Sean Menarguez, Director of Investor RelationsMr. Maher Masoud, Exec. VP, Gen. Counsel & Sec. (Age 47)Mr. Thomas Michael Ross, Exec. VP of Global Sales (Age 61)Mr. Kevin Gutshall, VP of Strategy & Corp. Devel.Dr. James Brady Ph.D., Sr. VP of Technical Applications & Customer SupportDr. Sarah Haecker Meeks Ph.D., Sr. VP of Bus. Devel. Who are some of MaxCyte's key competitors? Some companies that are related to MaxCyte include Sernova (SVA), Profound Medical (PRN), Profound Medical (PRN), Renalytix (RENX), Akumin (AKU), SQI Diagnostics (SQD), Oncimmune (ONC), Yourgene Health (YGEN), Verici Dx (VRCI), VentriPoint Diagnostics (VPT), Cambridge Cognition (COG), GeneNews (GEN), LexaGene (LXG), GENinCode (GENI) and genedrive (GDR). View all of MXCT's competitors. What other stocks do shareholders of MaxCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), (ATE), Astrotech (ASTC), Arcturus Therapeutics (ARCT), (AQB), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX) and Applied Genetic Technologies (AGTC). What is MaxCyte's stock symbol? MaxCyte trades on the London Stock Exchange (LON) under the ticker symbol "MXCT." How do I buy shares of MaxCyte? Shares of MXCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is MaxCyte's stock price today? One share of MXCT stock can currently be purchased for approximately GBX 387.50. How much money does MaxCyte make? MaxCyte (LON:MXCT) has a market capitalization of £393.47 million and generates £38.99 million in revenue each year. How many employees does MaxCyte have? MaxCyte employs 84 workers across the globe. How can I contact MaxCyte? MaxCyte's mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The official website for MaxCyte is www.maxcyte.com. The company can be reached via phone at +1-301-9441700. This page (LON:MXCT) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here